How have ABOS and NYXH total returns compared?

Over the past 5 years, ABOS delivered -32.60% and NYXH delivered -45.84% annualized total return. Past performance doesn't predict future results.

Acumen Pharmaceuticals, Inc. (ABOS) vs Nyxoah S.A. (NYXH)

A side-by-side comparison of Acumen Pharmaceuticals, Inc. and Nyxoah S.A. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ABOS

Acumen Pharmaceuticals, Inc.

$149M

$2.07HealthcareDelayed quote: Oct 6, 2026, 12:05 PM EDT

NYXH

Nyxoah S.A.

$145M

$1.45HealthcareDelayed quote: Oct 6, 2026, 11:59 AM EDT

Total return — ABOS vs NYXH

growth of $100 · dividends reinvested · last 5y

ABOS -89.4% (-36.2%/yr)NYXH -94.8% (-44.6%/yr)ABOS compounded faster over this window

ABOS NYXH

ABOS vs NYXH: by the numbers

•ABOS is the larger company ($149M vs $145M market cap).
•Both run net losses; ABOS's is the smaller (0.00% vs -435.70% net margin).

Metrics side by side

Valuation

Metric	ABOS	NYXH
P/S ratio	N/A	5.54
P/B ratio	2.60	1.53

Profitability

Metric	ABOS	NYXH
Gross margin	0.00%	63.13%
Operating margin	0.00%	-827.76%
Net margin	0.00%	-435.70%
ROE	-183.44%	-120.33%
ROIC	-118.67%	-61.13%

Growth (annualized)

Metric	ABOS	NYXH
Revenue CAGR (5Y)	N/A	120.68%
Total return CAGR (5Y)	-32.60%	-45.84%

Frequently asked

How have ABOS and NYXH total returns compared?: Over the past 5 years, ABOS delivered -32.60% and NYXH delivered -45.84% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ABOS analysis Full NYXH analysis Interactive comparison tool

Dig into the metrics

Acumen Pharmaceuticals ROE Nyxoah ROE Acumen Pharmaceuticals operating margin Nyxoah operating margin Acumen Pharmaceuticals revenue growth Nyxoah revenue growth Acumen Pharmaceuticals free cash flow Nyxoah free cash flow

Acumen Pharmaceuticals & Nyxoah appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.